Wikipedia -WSS

Wikipedia

author：focus 2025-09-28 16:35:13 - browse：91

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

WSS

Readout Newsletter: What happened with Sarepta's Duchenne data

Meta's Zuckerberg and Chan on track to put $50 billion into science

The pink breast cancer awareness ribbon needs a redesign

Ransomware attacks on hospitals: Study outlines patient impact

Gain of function research would be limited under House proposal

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

focus

Wikipedia

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Does good food count as health care? Study aims to find out

Moonlake's readout produced a cash windfall. Risks remain

The pink breast cancer awareness ribbon needs a redesign

Anesthesiologist group: stop taking Ozempic before surgery

Cassava reveals details — and problems — with Alzheimer's study

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA has safety concerns on CRISPR

Drug repurposing or repositioning? The language matters

Congress must reauthorize a committee to support older Americans

focus

Paying for Covid pills will soon shift to insurers

Cassava reveals details — and problems — with Alzheimer's study

Readout Newsletter: What happened with Sarepta's Duchenne data

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

In key trial, Verve's treatment lowers cholesterol levels in patients

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

leisure time

hotspot

hotspot

explore